<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> is a key drug in the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but it causes severe <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We previously reported that <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (4 mg/kg, i.p., twice a week) induces mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> in the late phase in rats, and that spinal NR2B-containing <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) receptors are involved in the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated the involvement of Ca(2+)/calmodulin dependent protein kinase II (CaMKII), which is a major intracellular protein kinase and is activated by <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor-mediated Ca(2+) influx, in the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> in rats </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: An increase of CaMKII phosphorylation was found in the spinal cord (L(4-6)) of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-treated rats </plain></SENT>
<SENT sid="4" pm="."><plain>This increased CaMKII phosphorylation was reversed by intrathecal injection of a selective CaMKII inhibitor KN-93 (50 nmol, i.t.) and a selective NR2B <z:chebi fb="68" ids="48706">antagonist</z:chebi> Ro 25-6981 (300 nmol, i.t.) </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, <z:hpo ids='HP_0011009'>acute</z:hpo> administration of KN-93 (50 nmol, i.t.) strongly reversed the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> in von Frey test, while it did not affect the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> in <z:chebi fb="15" ids="15347">acetone</z:chebi> test </plain></SENT>
<SENT sid="6" pm="."><plain>Similarly, oral administration of <z:chebi fb="0" ids="45951">trifluoperazine</z:chebi> (0.1 and 0.3 mg/kg, p.o.), which is an <z:chebi fb="0" ids="35476">antipsychotic drug</z:chebi> and inhibits calmodulin, reduced both mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> and increased CaMKII phosphorylation </plain></SENT>
<SENT sid="7" pm="."><plain>On the other hand, <z:chebi fb="0" ids="45951">trifluoperazine</z:chebi> at the effective dose (0.3 mg/kg) had no effect on the paw withdrawal threshold in intact rats </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, <z:chebi fb="0" ids="45951">trifluoperazine</z:chebi> at the same dose did not affect the motor coordination in rota-rod test in intact and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-treated rats </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These results suggest that CaMKII is involved in the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced mechanical <z:mp ids='MP_0003177'>allodynia</z:mp>, and <z:chebi fb="0" ids="45951">trifluoperazine</z:chebi> may be useful for the treatment of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in clinical setting </plain></SENT>
</text></document>